Fibroblast growth factor signaling in embryonic and cancer stem cells  by Dvorak, Petr et al.
FEBS Letters 580 (2006) 2869–2874Minireview
Fibroblast growth factor signaling in embryonic and cancer stem cells
Petr Dvoraka,c,d,*, Dana Dvorakovab, Ales Hampla,c,d
a Department of Biology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic
b Department of Internal Medicine-Hematooncology, University Hospital Brno, Czech Republic
c Department of Molecular Embryology, Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic
d Center for Cell Therapy and Tissue Repair, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
Received 23 January 2006; accepted 30 January 2006
Available online 28 February 2006
Edited by Horst FeldmannAbstract Cancer stem cells are cancer cells that originate from
the transformation of normal stem cells. The most important
property of any stem cell is the ability to self-renew. Through
this property, there are striking parallels between normal stem
cells and cancer stem cells. Both cell types share various markers
of ‘‘stemness’’. In particular, normal stem cells and cancer stem
cells utilize similar molecular mechanisms to drive self-renewal,
and similar signaling pathways may induce their diﬀerentiation.
The ﬁbroblast growth factor 2 (FGF-2) pathway is one of the
most signiﬁcant regulators of human embryonic stem cell
(hESC) self-renewal and cancer cell tumorigenesis. Here we
summarize recent data on the eﬀects of FGF-2 and its receptors
on hESCs and leukemic stem/progenitor cells. Also, we discuss
the similarities of these ﬁndings with stem cell renewal and diﬀer-
entiation phenotypes.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Fibroblast growth factors (FGFs) comprise a large family of
signaling molecules with various functions in development as
well as in adult physiology and pathology. FGF-2 (also called
basic FGF; bFGF), a prototype member of the FGF family, is
encoded by a single copy gene that is alternatively translated to
produce one low (18-kDa) and four high (22-, 22.5-, 24-, and
34-kDa) molecular mass isoforms [1,2]. The 18-kDa low
molecular mass (LMM) FGF-2 lacks a detectable secretion
signal sequence and is released via its association with other
molecules (e.g. HSP27) by an exocytotic mechanism that is
independent of the endoplasmatic reticulum/Golgi pathway
[3]. Cytosolic 18-kDa FGF-2 harboring a C-terminal nuclear
localization sequence (NLS) is speciﬁcally targeted to the
nucleus [4,5] by a mechanism involving the cytoplasmic
microtubule-associated protein translokin [6]. The high molec-
ular mass (HMM) isoforms of FGF-2 all contain classical
N-terminal NLS, and their nuclear localization can be further
enhanced through their association with the 53/55-kDa FGF-*Corresponding author. Fax: +420 549491327.
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doi:10.1016/j.febslet.2006.01.0952-interacting factor (FIF) [7]. In theory, FIF could interact
with LMM FGF-2, which is also translocated into the nucleus,
since the FIF-binding motif of FGF-2 is located in the last 155
amino acids of FGF-2 and not in the NH2-extension that is
speciﬁc for HMM isoforms of FGF-2 [7]. The nuclear accumu-
lation of HMM FGF-2 is associated with its post-translational
methylation [8], which may be crucial for protein–protein or
protein–RNA interactions in the nuclear environment [9].
The diﬀerent subcellular localization and traﬃcking of the
FGF-2 isoforms unambiguously determine their mode of
action. LMM FGF-2 signals via its interaction with the
high-aﬃnity transmembrane FGF receptors (FGFR1-4) in a
paracrine or autocrine manner. Importantly, FGFR-ligand
binding studies demonstrated that LMM FGF-2 binds pre-
dominantly to FGFR1 and 2 [10,11]. Moreover, high-aﬃnity
binding is extracellularly modulated by non-signaling hepa-
rin/heparan sulfate (HS) proteoglycans that are subsequently
involved in the intracellular processing of FGF-2 [12]. HS pro-
teoglycans are also unconditionally required for ligand-in-
duced dimerization and transphosphorylation of FGFRs, the
key events by which tyrosine kinase receptors initiate down-
stream signaling (reviewed in [13]). The signaling cascade
downstream of the FGFRs involves tyrosine phosphorylation
of the docking protein FRS2 followed by recruitment of sev-
eral Grb2 molecules. Next, activated Grb2 associated with
FRS2 recruits the nucleotide exchange factor SOS. The forma-
tion of FRS2-Grb2-SOS complexes results in activation of the
Ras-Raf-MAPK signaling pathway that initiates a cell re-
sponse. In parallel, FGFRs can also activate the PLCc–PKC
pathway in which Grb2 molecules recruit the docking protein
Gab1 leading to the activation of the PI3K-Akt cell survival
pathway. Thus, FGF signaling through FGFRs is mediated
primarily by the assembly of multi-docking protein complexes
and involves multiple layers of regulation [14].
In contrast to the relatively well-understood paracrine/auto-
crine activities of LMM FGF-2, HMM FGF-2 possess recep-
tor-independent intracrine activities that are not easily
analyzed. It has been reported that HMM FGF-2 downregu-
lates PKCe and upregulates PKCd, an eﬀect which subse-
quently leads to the activation of ERK1/2 (MAPK) [15].
This ﬁnding suggests that HMM FGF-2 preferably utilizes
the PLC/PKC signaling pathways and may provide an alterna-
tive pathway from LMM FGF-2-mediated signaling [14].
Although the biological role of HMM FGF-2 is largely
unknown, these and other data suggest that the signaling
and nuclear localization of HMM FGF-2 allows for theblished by Elsevier B.V. All rights reserved.
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type of cells [1,16,17].
The complexity of FGF-2 signaling via its cognate high-
aﬃnity receptors and the known or hypothetical cellular con-
sequences of such signaling with respect to human embryonic
stem cells (hESCs) and cancer stem cells are illustrated in
Fig. 1.2. Roles of FGF-2 in hESCs
Despite a concentrated eﬀort by many researchers, the sig-
naling pathways involved in the self-renewal and maintenance
of the pluripotent status of hESCs are still largely unexplored.
It is widely accepted that hESCs require exogenous FGF-2 to
sustain self-renewal and the capacity to diﬀerentiate into a
large number of somatic cell types [18,19]. However, under-Fig. 1. Schematic diagram of FGFR and possible modes of FGF-2 actio
proteoglycans (HSPGs) or their side chains (small beige circles). The result
domains II and alternatively spliced IIIb/IIIc; DII and DIIIb/IIIc) and the
receptor. The subsequent receptor dimerization brings the cytoplasmic tyro
transphosphorylation (rightarrow, P). This tri-molecular arrangement trigge
assembly, and phosphorylation (P) of downstream signaling proteins (blue
aﬃnity receptors, primarily FGFR1, and the resulting complex is internaliz
functions to activate genetic programs related to cell growth, diﬀerentiation,
(III) Endogenously synthesized LMM FGF-2, lacking an obvious signal sequ
released in complex with various molecules (e.g. HSP27 (light blue oval)) o
Additionally, this LMM FGF-2 can be embedded and eﬃciently exported in
exported, LMM FGF-2 induces cellular signaling in an autocrine or paracrine
FIF (dark blue oval) and is directly transported into the nucleus where mediat
impact on each cell type may be entirely diﬀerent, the complex actions of exo
perform the diverse cellular functions that are shared by human embryonicstanding the molecular regulation of FGF signaling in hESCs
remains a major challenge.
The ﬁrst step in understanding the role of FGF-signaling in
hESCs is to examine the expression of individual components
of the FGF signaling pathway. Using cDNAmicroarray analy-
sis, several groups have described elevated levels of key regula-
tors of the FGF pathway in undiﬀerentiated hESCs compared
with their diﬀerentiated counterparts. These diﬀerentiated
counterparts were obtained following the formation of embry-
oid bodies which exhibited long-lasting (3–5 weeks) non-speciﬁc
diﬀerentiation. The upregulated FGF signaling components
identiﬁed include FGF-2, FGF-11, and FGF-13, and all four
FGFRs [20–25]. Importantly, using real time RT-PCR, we
determined that the expression of the FGFRs in undiﬀerenti-
ated cells follows a speciﬁc pattern with FGFR1 being the most
abundant receptor and other receptors showing lower expres-
sion in the following order: FGFR3 > FGFR4 > FGFR2. Inn. (I) Exogenous FGF-2 (red ovals) associates with heparin sulfate
ing complex binds to the ligand-binding site (immunoglobulin[Ig]-like
heparin-binding region (Ig-like domain II; DII) of the high-aﬃnity
sine kinase (TK) domains into close proximity allowing for receptor
rs the ‘‘classical’’ transduction pathway that consists of recruitment,
squares). (II) The exogenous LMM isoform of FGF-2 binds to high-
ed and translocated into the nucleus. There, this complex presumably
and (in the case of hESCs) an adaptive response to in vitro conditions.
ence for active secretion via endoplasmatic reticulum/Golgi pathway, is
r targeted to the nucleus via association with translokin (pink oval).
membrane-derived microvesicles [our unpublished observation]. Once
manner. (IV) Endogenously synthesized HMM FGF-2 associates with
es its pro-survival and anti-apoptotic activities. Although the biological
genous and endogenous FGF-2 described above may be coordinated to
stem cells and leukemia progenitor/stem cells.
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hESCs are induced to diﬀerentiate for 8–15 days using various
stimuli, the expression of all four FGFRs increases [26]. The
inconsistency of the results obtained when using long-lasting
or shorter diﬀerentiation protocols suggests a tight regulation
of FGFRs regulation during cell speciﬁcation. Also, it is inter-
esting that the most abundant receptor, FGFR1, is the domi-
nant target of exogenous FGF-2. In neural cells, FGFR1 has
been demonstrated to enter into the nucleus with its ligand
(FGF-2) where it acts as a general transcriptional regulator of
the genes involved in cell growth and diﬀerentiation [27]. The
expression of FGF-2 and its receptors in undiﬀerentiated
hESCs and hESC-derived embryoid bodies was also examined
using massively parallel signature sequencing [28]. These results
also clearly demonstrate that hESCs express the docking pro-
tein FRS2, which is a major target of activated FGFRs. In con-
junction with transcriptome analysis, we determined that
undiﬀerentiated hESCs as well as hESCs at the early stages of
diﬀerentiation express several molecular mass isoforms of
FGF-2, including those that are exportable as well as those that
are nuclear localized [26]. Recently, we demonstrated that,
when FGF-2-enriched hESCs are subjected to an extended dif-
ferentiation protocol (2–3 weeks of diﬀerentiation as embryoid
bodies), the expression of endogenous FGF-2 remarkably
diminishes [our unpublished data]. Together, several studies
have clearly demonstrated that undiﬀerentiated as well as diﬀer-
entiated hESCs are ready to accept and transmit FGF signals.
In addition, the diﬀerential expression of multiple exportable
and nuclear forms of FGF-2 clearly suggests that this signaling
pathway may function in an autocrine or intracrine manner in
undiﬀerentiated cells, while the exogenous FGF-2 may repre-
sent the key activity driving these cells to form specialized cell
types during their diﬀerentiation.
The second step in understanding the complexities of FGF
signaling in hESCs is to examine the biological eﬀects of exog-
enous FGF-2 on the growth of hESCs. FGF-2 supports growth
of undiﬀerentiated cells and increases cloning eﬃciency
[18,19,29,30]. Although it is widely used, the molecular mecha-
nism(s) responsible for this eﬀect is not understood. Interest-
ingly, in our experiments, the outgrowth of hESC colonies in
medium containing increased concentrations of exogenous
FGF-2 (>5 ng/ml) was reduced while their proliferation rate
was not aﬀected [26]. This observation suggests that exogenous
FGF-2 can modulate cell attachment and spreading, likely via
the induction of cell adhesion molecules. Such indirect eﬀect
might also be involved, at least partially, in the phenomenon
of culturing hESCs in feeder-free conditions which absolutely
requires extremely high concentration of FGF-2 (40 ng/ml),
either alone [31] or in combination with noggin [32,33]. The sim-
plest explanation for this result is that exogenous FGF-2 syner-
gizes with noggin to repress trophoblast-inducing BMP
signaling and thus sustains the undiﬀerentiated growth of
hESCs [32,33]. The importance of the FGF signaling pathway
in maintaining the pluripotency of hESCs was recently demon-
strated by two experiments in which inhibition of the FGFR
tyrosine kinase activity caused rapid diﬀerentiation. Our study
[26] showed that LMM FGF-2 is released by hESCs into the
medium where it can signal via an autocrine pathway. We fur-
ther demonstrated that the inhibition of such autocrine FGF
signaling using the synthetic inhibitor of FGFRs, SU5402, sup-
pressed the activation of signaling molecules downstream of
FGFRs, downregulated Oct-4, upregulated p27Kip1, and ledto rapid diﬀerentiation. Recently, we performed cDNA micro-
array analysis to examine mRNA expression patterns in hESCs
cultured either in medium without FGF-2 supplemented with
SU5402 (to inhibit autocrine signaling) or in standard FGF-2-
containing medium (4 ng/ml). Cells cultured in medium without
FGF-2 served as controls. We observed characteristic gene
expression changes under both conditions; however, number
of diﬀerentially expressed genes as well as the magnitude of
the fold-changes of these genes were consistently much higher
in cells maintained with SU5402 [our unpublished data]. There-
fore, it is possible that the endogenously-produced FGF-2
including the exportable 18-kDa isoform may signiﬁcantly reg-
ulate the phenotype of hESCs. Other studies [34] also demon-
strated that treatment of hESCs with SU5402 causes hESC
diﬀerentiation and suggested that FGF-2 acts as a competence
factor in the activin/nodal/TGFb pathway. In addition, they de-
scribed a chemically deﬁned medium supplemented with a com-
bination of activin or nodal and FGF-2 in which hESCs
maintain long-term pluripotency in the absence of feeder cells,
conditioned medium, or serum replacer.
Together, it is now clear that FGF signaling is uncondition-
ally required for the sustained self-renewal and pluripotency of
hESCs. However, understanding the basic molecular mecha-
nisms regulating this eﬀect and its consequences on other sig-
naling pathways is still very limited.3. Roles of FGF-2 and FGFRs in human hematologic
malignancies
A number of studies describing the positive eﬀects of FGF-2
on normal hematopoietic development have been reported
[35–37]. These eﬀects typically utilize the common activities
of several mesoderm-inducing factors and are involved in the
early stages of hematopoietic commitment. During adult
hematopoiesis, FGF-2 has been shown to synergize with other
hematopoietic growth factors to stimulate the growth of pro-
genitor cells. For example, LMM FGF-2 was shown to coop-
erate with v-Myb to control the sustained proliferation of
erythroid progenitors, which would otherwise eﬀectively diﬀer-
entiate [38]. It was also shown that the clonogenic growth of
hematopoietic progenitor cells obtained from granulocyte
macrophage colony-stimulating factor-mobilized bone marrow
cells is augmented in the presence of high concentrations of
stem cell factor (SCF) and FGF-2 (100 ng/ml) [39]. Exogenous
FGF-2 also enhances the growth of bone marrow mesenchy-
mal stem cells [40]. This eﬀect is likely mediated by the FGF-
2-induced stimulation of telomere elongation that was shown
to prolongs the life span and modulates the diﬀerentiation po-
tential of bone marrow stromal cells [41]. In addition to the rel-
atively well-understood eﬀects of exogenous FGF-2 on
hematopoietic stem/progenitor cells, normal adult hematopoi-
esis might also be regulated by FGF-2 intracrine or autocrine
signals. Human CD34+ progenitor cells have been shown to
synthesize and secrete numerous growth factors, including
FGF-2. It has been suggested that FGF-2 produced by these
cells stimulates the proliferation of other cell types, such as
endothelial cells [42], although, its intracrine activities remain
completely unknown.
Importantly, the biological eﬀects of either endogenous or
exogenous FGF-2 may have diﬀerent signiﬁcance in trans-
formed cells, an eﬀect that may potentially relate to their
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cable, examples of non-hematopoietic cancers that support this
hypothesis. It has been shown that elevated levels of FGF-2 in
the micro-environment of metastatic prostate tumors provides
a mechanism by which cancer cells are able to counteract the
anti-proliferative and cell-killing eﬀects of chemotherapy.
Since these protective eﬀects could be reversed with the addi-
tion of an FGF-2 antibody, it was suggested to involve speciﬁc
interactions between FGF-2 with its cognate receptors [43].
Another example of how FGF-2 contributes to the malignant
phenotype of cancer cells involves the targeting of rat bladder
carcinoma cells with nuclear 24-kDa FGF-2. These cells be-
come highly tumorigenic and metastatic [44], likely due to
the dramatic activation of their cell survival program [45].
Although FGF-2 has been shown to promote the neovascu-
larization of solid tumors, its eﬀects in hematological malig-
nancies are largely unknown. Current models of this eﬀect
suggest that aberrant expression of speciﬁc growth factors in
a variety of cancer cell types, including leukemia cells, can con-
fer a growth advantage and, thus, contribute to a tumorigenic
phenotype. Therefore, our laboratory has focused on the level
of plasma FGF-2 and the spectrum of the FGF-2 molecular
mass isoforms in peripheral white blood cells (WBCs) from a
large sample of patients with various neoplastic disorders of
the hematopoietic system, such as B cell chronic lymphocytic
leukemia (B-CLL), chronic myeloid leukemia (CML),
myelodysplatic syndrome, acute myeloid leukemia, acute lym-
phoblastic leukemia, and hairy cell leukemia. We demon-
strated that the level of plasma FGF-2 is elevated in about
50% of patients suﬀering from B-CLL and CML. Importantly,
the WBCs from B-CLL patients express both exportable and
nuclear-localized variants of FGF-2, whereas the WBCs from
CML patients have a weak expression of nuclear FGF-2 iso-
forms. Furthermore, while FGFRs expressed in WBCs from
B-CLL patients bind only weakly 18-kDa FGF-2, the FGFRs
expressed in WBCs from CML patients bind FGF-2 more
strongly. As a consequence of this stronger binding, exogenous
FGF-2 activates the signal cascade downstream of FGFRs in
and stimulates the growth of WBCs from CML patients [46].
These results were conﬁrmed in model leukemia cell lines
[47]. We also demonstrated that nuclear HMM FGF-2 associ-
ates with FIF [47], a ﬁnding similar to that observed in hESCs.
Therefore, we concluded that WBCs in CML patients are able
to utilize 18-kDa FGF-2 provided by other FGF-2-hyperpro-
ducing cells to activate downstream targets and presumably
modulate their cell growth. While searching for the source of
this FGF-2 in the blood of CML patients, we identiﬁed a very
minor subpopulation of CML CD34+ BCR-ABL+ progenitor
cells which contain low levels of secretable 18-kDa FGF-2 and
very high levels of nuclear 22-, 22.5-, 24-, and 34-kDa FGF-2.
These cells most likely represent the source of the HMM FGF-
2 detected in the extract from total WBCs [48]. Considering the
activities of exportable LMM and nuclear HMM FGF-2 iso-
forms in various cell types, there are several abnormalities of
CD34+ BCR-ABL+ cells that have been previously ascribed
to FGF-2-unrelated mechanisms which may involve endoge-
nous FGF-2. For example, CML CD34+ cells are resistant
to anti-leukemic drug-induced apoptosis and have sustained
activation of the MAPK pathway, aberrant cycling and diﬀer-
entiation, and activated transcription and production of sev-
eral hematopoietic cytokines that serve as autocrine
mediators of proliferation. It is likely that the abnormal accu-mulation of FGF-2 in these cells produces a pro-leukemic ef-
fect(s) in addition to the key molecular event, the BCR-ABL
translocation.
Neoplastic transformation is often related to abnormal acti-
vation of growth factor receptors. For example, in multiple
myeloma (MM), the presence of the translocation t(4;14) re-
sults in the dysregulated expression of FGFR3 [49]. As a con-
sequence, the constitutively activated kinase domain of
FGFR3 signals to promote MM cell proliferation and sur-
vival. Additionally, fusions between the catalytic domain of
FGFR1 and several partner genes (the most common is the
zinc ﬁnger transcription factor ZNF198) result in the constitu-
tive activation of the FGFR1 tyrosine kinase that is highly
transforming and associated with stem cell myeloproliferative
disorder (MPD) [50]. An alternative fusion that occurs very
rarely in CML cells is the fusion between FGFR1 and BCR
[51]. This fusion also shows high transforming activity and
potentiates the growth factor independence of malignant pro-
genitor cells. Therefore, in both malignancies, dysregulated
FGFR1 and 3 provide important molecular targets of ki-
nase-speciﬁc small molecule inhibitors which could mediate
the decreased viability and growth arrest of cancer cells
[51,52].
Work by our laboratory has also demonstrated that the
expression of the myeloma-associated oncogene FGFR3 is in-
creased in cancer cells from patients with CML and that this
expression is decreased following the successful transplanta-
tion of stem cells [53]. Furthermore, we determined that highly
enriched CML CD34+ cells express signiﬁcantly increased lev-
els of FGFR3 compared to either their normal counterparts or
diﬀerentiated CML CD34- progeny. Interestingly, this in-
creased level of FGFR3 was eﬃciently inhibited by the
BCR-ABL tyrosine kinase inhibitor, imatinib [54]. This ﬁnding
again suggests the involvement of FGFR3 in malignant hema-
topoiesis.
Together, these ﬁndings related to cancer stem cells have
clear implications for the involvement of the FGF signaling
pathway in the genesis of hematological malignancies. How-
ever, the practical beneﬁcial eﬀects of potential therapies can
only result from a greater understanding of the molecular biol-
ogy of the individual components of the FGF pathway. Such
an understanding can even be achieved by investigating nor-
mal stem cells.4. Common elements and functional relationships of the FGF-2
pathway in hESCs and leukemic stem/progenitor cells
As described in this review, hESCs maintained in long-term
cultures and hematopoietic stem/progenitor cells obtained di-
rectly from patients suﬀering from leukemia show similarly in-
creased expression of endogenous FGF-2 that is either
exported out of cells or targeted into the nucleus. Both types
of stem cell are well-equipped to accept and transmit exoge-
nous FGF signals and to execute an appropriate cellular re-
sponse. Thus, the functional involvement of the FGF
signaling pathway in the regulation of stem cell fate is likely
very important.
Our studies suggest that FGF-2 signaling participates in the
self-renewal and maintenance of an undiﬀerentiated state of
hESCs, whereas dysregulated expression of FGF-2 and its
receptors in cancer cells increases their transforming activity.
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ferentiated hESCs may reﬂect adaptation to long-term culture
in vitro followed by selection and forced activation of those
signaling pathways that are advantageous for survival and
the maintenance of the undiﬀerentiated phenotype. Utilizing
the cancer stem cell model, the dysregulation of the FGF-2 sig-
naling pathway in malignant cells may resemble such a ‘‘cul-
ture adaptation’’ of abnormal cells in vivo, which would
provide a growth advantage and self-renewal stimulation to
cancer stem cells. As a consequence, this ‘‘adaptation’’, which
is similarly manifested in both stem cell types, provides an
important advantage for maintaining long-term culture of
undiﬀerentiated hESCs and an important disadvantage for
the selective elimination of cancer stem cells by various apop-
tosis-inducing drugs. Therefore, it is tempting to speculate that
the inhibition of the FGF signaling pathway may induce sim-
ilar diﬀerentiation eﬀects in both stem cell types.5. Future directions
Accumulation of endogenous FGF-2 and its autocrine/intra-
crine activities important for the maintenance of the undiﬀer-
entiated phenotype are common events in both embryonic
stem cells and leukemic stem/progenitor cells. Therefore, it will
be important to speciﬁcally and eﬀectively inhibit nuclear-tar-
geted FGF-2 expression (e.g. by short hairpin RNAs) to assess
accurately the importance of this signaling pathway on cellular
response and cell fates. Additionally, it will be important to
examine the molecular mechanisms by which the expression
of endogenous FGF-2 becomes downregulated upon diﬀeren-
tiation. The manipulation of one or several components of
the FGF signaling pathway may have critical implications in
the controlled diﬀerentiation of hESCs which may be impor-
tant for the establishment of certain cell therapies and, in the
case of leukemic stem/progenitor cells, the development of a
targeted approach for the treatment of leukemia.
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